Skip to content

Depression: all studies

Page 476 of 1,036: studies 4,751 to 4,760 of 10,358, newest first. Back to the depression overview

Research

Integrative Use of Esketamine and Psychotherapy in a Real-World Outpatient Setting: A Mixed-Methods Case Series

European Psychiatry June 1, 2026 Nawfel Ayad, Samer Makhoul, F. Alkhaja

Introduction Treatment-resistant depression remains a major clinical challenge, with many patients experiencing relapse despite advances in medication and psychotherapy. Esketamine offers rapid relief from depressive symptoms, while psychotherapy helps patients build lasting skills to manage their condition. Despite their individual effectiveness, little is known about how these treatments work...

Care Next Door: Community Outpatient Esketamine Across Urban and Rural Clinics

European Psychiatry June 1, 2026 Jesús García-Jiménez, S. Posik, B. Herrejón et al.

Introduction Treatment-resistant depression (TRD) is highly burdensome. Intranasal esketamine is effective, yet hospital-centric delivery adds travel and continuity barriers that may hinder adherence and outcomes. We hypothesize that community outpatient, patient-proximal delivery —often with the patient’s usual psychiatrist—improves effectiveness, engagement and acceptability, consistent with...

Esketamine nasal spray: real world use in the Department of Mental Health of Rimini (Italy)

European Psychiatry June 1, 2026 M. P. Rapagnani, L. Veronesi, F. Sartini

Introduction In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments of antidepressants. Esketamine (the S-enantiomer of ketamine) nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonine-norepinephrine reuptake inhibitor (SNRI), is the only treatment approved in Europe...

Ketamine: Navigating Risk and Benefit. the Margaret Slack Travelling Fellowship

BJPsych Open June 1, 2026 Rebecca Mcknight, Shanthi Sarma

Aims: Treatment-resistant depression (TRD) is common and associated with substantial disability and economic burden. It is estimated to affect over 100 million people worldwide and approximately 2.7 million people in the United Kingdom. Ketamine has emerged as a novel therapy for TRD, with studies demonstrating rapid antidepressant effects. However, ketamine is also used recreationally and can...

The use of ketamine in the management of suicidal crisis: a literature review

European Psychiatry June 1, 2026 A. Rami

Introduction Suicidal crisis represents a major psychiatric emergency, often occurring in the context of mood disorders and requiring rapid, effective interventions. Traditional antidepressant treatments usually have a delayed onset of action, underscoring the need for fast-acting therapeutic alternatives. In recent years, ketamine—an NMDA receptor antagonist—has emerged as a promising option...

Psychedelic Renaissance: A New Paradigm in Mental Health

European Psychiatry June 1, 2026 A. M. Matas Ochoa, A. R. Quiroga, I. D. Sacristán

Introduction Psychedelics are hallucinogenic agents that are awakening scientific interest in recent years, especially in the field of mental health. Psychedelics induce non-ordinary states of consciousness and alterations in the emotions and in cognition and could be beneficial in treating some mental illness. Objectives The objective of the poster is to expand knowledge about emerging...

HJ-006: A Non-Hallucinogenic Synaptogenic Compound with Rapid and Sustained Antidepressant Efficacy

European Psychiatry June 1, 2026 L. Zeng, Y. Chen, Y. Liu et al.

Introduction Current antidepressants (SSRIs/SNRIs) face limitations including delayed onset (4–6 weeks) and modest efficacy (~50% response rates), while serotonergic psychedelics show rapid antidepressant potential via 5-HT2A agonism and synaptic plasticity but are hindered by hallucinogenic activity and 5-HT2B-mediated cardiotoxicity. Objectives To address these challenges, we characterize...

MM120 (Lysergide) May Enhance Neuroplasticity by Post-Dose Upregulation of TrkB

European Psychiatry June 1, 2026 G. Smagin, J. Tripp

Introduction MM120 (lysergide D-tartrate, a formulation of LSD) is under development as a potential treatment for generalized anxiety and major depressive disorders. How psychedelic drugs interact at the TrkB receptor, a key target of neuroplasticity, is not reported. Objectives The study evaluated binding and functional activity of known serotonergic psychedelic compounds and SRI fluoxetine at...

Efficacy of Mindfulness-Based Cognitive Therapy in the Recovery Phase of Schizophrenia

European Psychiatry June 1, 2026 H. C. Zhang

Introduction Background: Individuals in the recovery phase of schizophrenia often face persistent challenges including residual symptoms, emotional dysregulation, cognitive deficits, and high relapse rates. Mindfulness-Based Cognitive Therapy (MBCT), effective in mood disorders, shows promise as an adjunctive intervention but requires rigorous evaluation in schizophrenia recovery.Background:...

DOI: 10.1192/j.eurpsy.2026.10914 (opens in new tab) Full text (opens in new tab) Anxiety Mindfulness-based cognitive therapy Schizophrenia object-oriented programming Mood +11

Visual Imagery and Trauma: A PRISMA-Guided Narrative Review on the Neurocognitive and Psychiatric Implications of Aphantasia in PTSD

European Psychiatry June 1, 2026 N. Northover, S. Kolloju, N. Ibrahim et al.

Introduction Aphantasia, the inability to voluntarily generate mental visual images, may influence emotional processing and memory encoding. While its effects on memory and cognition have been studied, its role in traumatic memory and PTSD remains underexplored. Understanding how aphantasia interacts with PTSD, depression, and social phobia is crucial, underscoring the need for further...